Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus

Area of Science:

• Immunology
• Cell Biology
• Dermatology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease causing widespread inflammation due to autoantibodies.
• Mitochondrial dysfunction, specifically hyperpolarized and adenosine triphosphate (ATP)-deficient mitochondria, is implicated in SLE pathogenesis.
• These mitochondria resist apoptosis, leading to necrosis and release of intracellular components, triggering autoimmune responses.

Purpose of the Study:

• To investigate the therapeutic potential of Ultraviolet (UV)-A1 photons in managing SLE.
• To elucidate the mechanisms by which UV-A1 radiation impacts mitochondrial function and cellular processes in SLE.

Main Methods:

• Exogenous exposure to low-dose, full-body UV-A1 radiation was investigated.
• The study examined the effects of UV-A1-generated singlet oxygen on mitochondrial polarization and apoptosis.
• Mechanisms of UV-A1 action, including HO-1 gene activation and direct effects on immune cells, were analyzed.

Main Results:

• UV-A1 radiation generates singlet oxygen, which depolarizes hyperpolarized mitochondria, promoting apoptosis over necrosis.
• Singlet oxygen activates the heme oxygenase (HO-1) gene, producing antioxidant and protective molecules (biliverdin, bilirubin, Fe, CO).
• UV-A1 photons directly reduce B cell activity, preserve cell-mediated immunity, slow epigenetic progression of SLE, and improve cutaneous lupus manifestations.

Conclusions:

• UV-A1 phototherapy offers a promising, safe, and manageable treatment for SLE by addressing core disease mechanisms.
• The therapy normalizes mitochondrial function, reduces systemic inflammation, and provides multi-faceted benefits for SLE patients.
• UV-A1 irradiation demonstrates potential in reducing autoantibodies and protecting against complications during lupus pregnancy.